Hikma Pharmaceuticals Plc (LON:HIK) had its price target lowered by equities research analysts at J P Morgan Chase & Co from GBX 1,500 ($19.93) to GBX 1,250 ($16.61) in a report issued on Friday, October 6th. The firm currently has a “neutral” rating on the stock. J P Morgan Chase & Co’s price objective would indicate a potential upside of 5.49% from the stock’s current price.
HIK has been the subject of a number of other research reports. Jefferies Group LLC dropped their target price on shares of Hikma Pharmaceuticals Plc from GBX 1,450 ($19.27) to GBX 1,390 ($18.47) and set an “underweight” rating for the company in a research report on Wednesday, June 28th. Barclays PLC dropped their target price on shares of Hikma Pharmaceuticals Plc from GBX 2,200 ($29.23) to GBX 1,500 ($19.93) and set an “overweight” rating for the company in a research report on Friday, August 25th. Goldman Sachs Group, Inc. (The) cut shares of Hikma Pharmaceuticals Plc to a “neutral” rating and dropped their target price for the stock from GBX 2,600 ($34.55) to GBX 1,310 ($17.41) in a research report on Tuesday, August 22nd. HSBC Holdings plc dropped their target price on shares of Hikma Pharmaceuticals Plc from GBX 1,700 ($22.59) to GBX 1,410 ($18.74) and set a “reduce” rating for the company in a research report on Tuesday, June 27th. Finally, Citigroup Inc. reissued a “neutral” rating and set a GBX 1,550 ($20.60) price objective on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of GBX 1,551.45 ($20.61).
Shares of Hikma Pharmaceuticals Plc (HIK) opened at 1185.00 on Friday. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,101.00 and a 12 month high of GBX 2,346.00. The stock’s market cap is GBX 2.84 billion. The firm has a 50-day moving average price of GBX 1,188.08 and a 200-day moving average price of GBX 1,496.17.
TRADEMARK VIOLATION NOTICE: “J P Morgan Chase & Co Cuts Hikma Pharmaceuticals Plc (HIK) Price Target to GBX 1,250” was first posted by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://baseballnewssource.com/markets/hikma-pharmaceuticals-plc-hik-given-new-gbx-1250-price-target-at-j-p-morgan-chase-co/1702927.html.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with our FREE daily email newsletter.